GDF-15: Mechanism, Dosing & Research Data

GDF-15 is a stress-responsive member of the TGF-beta superfamily that acts as the primary endogenous ligand for the GFRAL receptor expressed in the hindbrain. It is a potent regulator of food intake, body weight, and nausea, circulating at low picomolar levels basally and rising dramatically during illness, cancer cachexia, pregnancy, and metformin use. GDF-15 analogs are in late-stage clinical development for obesity and metabolic disease.

Mechanism of Action

GFRAL/RET complex in area postrema (outside blood-brain barrier) detects circulating GDF-15 and relays signals via vagal afferents to hypothalamus and brainstem satiety centers
Potently suppresses food intake and body weight; GDF-15 infusion reduces caloric intake by 40-70% acutely in rodents and humans
Induces nausea and aversion via area postrema; likely the mechanism behind cancer cachexia-associated anorexia and metformin GI side effects
Elevated chronically in metabolic disease, heart failure, CKD, and cancer; GDF-15 rise is adaptive stress response to protect against nutrient overload
Anti-inflammatory at low doses via GFRAL-independent pathways in macrophages; reduces TNF-alpha and IL-6 in some contexts

Research Findings

Metformin raises GDF-15 by 2-3-fold in T2D patients; GDF-15 elevation accounts for significant portion of metformin-induced weight loss and GI intolerance
GFRAL knockout mice are resistant to GDF-15-induced anorexia, confirming GFRAL as the essential receptor for metabolic effects
Pizuglanstat (AZD9550), a GDF-15 analog, reduced body weight 6-10% in Phase II trials for obesity with acceptable tolerability
GDF-15 serum levels predict mortality in heart failure, renal disease, and cancer; strong prognostic biomarker independent of natriuretic peptides
Pregnancy induces 10-50-fold rise in GDF-15 (placental secretion); hypothesized to cause nausea/vomiting of pregnancy (morning sickness)

Research Protocols

Pharmacological: GDF-15 analogs (LY3463251, AZD9550) at 1-10 mg/kg SC or IV in rodent diet-induced obesity models
Acute food intake: 1-10 nmol/kg IV GDF-15 in fasted rodents; measure food intake at 1, 2, 4 hours
Biomarker: serum GDF-15 by ELISA; normal range 150-1150 pg/mL; >4000 pg/mL associated with adverse cardiovascular outcomes
GFRAL binding assay: GDF-15 Kd ~0.2-1 nM at GFRAL/RET complex

Interactions

Metformin: raises endogenous GDF-15; partially mediates metformin weight loss and GI side effects
GLP-1 receptor agonists: additive weight loss; complementary mechanisms (GDF-15 via hindbrain GFRAL, GLP-1 via vagal/CNS GLPR)
GFRAL antagonists (anti-GDF-15 antibodies): block anorectic and nauseating effects; being developed for cancer cachexia

Safety Profile

GDF-15 analogs cause dose-dependent nausea and vomiting (on-target GFRAL effect). Phase II trials showed 10-20% nausea incidence, manageable with slow titration. No significant cardiovascular or metabolic adverse effects. Chronically elevated endogenous GDF-15 is a marker of disease burden, not a cause.